Adjuvant immunotherapy in older patients with stage III and resected stage IV melanoma: Toxicity and recurrence-free survival outcomes from the Dutch melanoma treatment registry
Older patients had similar benefit of adjuvant immunotherapy compared to older subgroups in previous trials. However, patients with multiple comorbidities were at increased risk of grade ≥ 3 irAEs and had a lower RFS. This should be considered when deciding upon adjuvant treatment.
Authors
- Martin W. Bloem (ORCID: https://orcid.org/0000-0001-6686-5929)
- Astrid A.M. van der Veldt (ORCID: https://orcid.org/0000-0003-0446-1907)
- Geke A.P. Hospers (ORCID: https://orcid.org/0000-0002-3047-7892)
- Willeke A.M. Blokx (ORCID: https://orcid.org/0000-0002-4647-8830)
- Djura Piersma (ORCID: https://orcid.org/0000-0001-5233-0296)
- Ellen Kapiteijn (ORCID: https://orcid.org/0000-0002-4814-6426)
- Gerard Vreugdenhil (ORCID: https://orcid.org/0000-0002-8816-1540)
- A M Stevense-den Boer
- Johannes J. Bonenkamp
- N.A. de Glas
- Michel W.J.M. Wouters (ORCID: https://orcid.org/0000-0001-6173-0662)
- Johanneke E. A. Portielje (ORCID: https://orcid.org/0000-0002-0246-1631)
- J.B. Haanen
- Alfons J.M. van den Eertwegh (ORCID: https://orcid.org/0000-0003-2196-1233)
- Frederiek van den Bos (ORCID: https://orcid.org/0000-0003-1426-3509)
- Karijn P.M. Suijkerbuijk (ORCID: https://orcid.org/0000-0003-3604-5430)
- R.S. van Rijn (ORCID: https://orcid.org/0000-0001-5608-706X)
- A. Özkan (ORCID: https://orcid.org/0000-0002-6729-9479)
- Franchette W.P.J. van den Berkmortel
- C E Holtslag
- Jan Willem B. de Groot (ORCID: https://orcid.org/0000-0002-1043-5011)
- C. Blank
- M. J. Boers‐Sonderen
- Maureen J B Aarts
Institutions
- University Medical Center Groningen (NL)
- Radboud University Nijmegen (NL)
- Utrecht University (NL)
- Heidelberg University (DE)
- Leiden University Medical Center (NL)
- Maastricht University Medical Centre (NL)
- Medisch Spectrum Twente (NL)
- Erasmus MC (NL)
- University Hospital Heidelberg (DE)
- Medisch Centrum Leeuwarden (NL)
- Radboud University Medical Center (NL)
- The Netherlands Cancer Institute (NL)
- University Medical Center Utrecht (NL)
- Dutch Institute for Clinical Auditing (NL)
- Amphia Ziekenhuis (NL)
- Oncode Institute (NL)
- Máxima Medisch Centrum (NL)
- Zuyderland Medisch Centrum (NL)
- Isala (NL)
- Cancer Center Amsterdam (NL)
- Amsterdam UMC Location Vrije Universiteit Amsterdam (NL)
- Erasmus University Rotterdam (NL)
Publication Details
- Journal
- European Journal of Cancer
- Published
- 2024-09-30
- DOI
- https://doi.org/10.1016/j.ejca.2024.115056
- Citations
- 9
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 2.54
Funders
- Bristol-Myers Squibb
- Les Laboratories Pierre Fabre
- Universiteit Leiden
- ZonMw
- Leids Universitair Medisch Centrum